Fda grants priority review for biologics license application (bla) and ema accepts marketing authorisation application (maa) for apitegromab as a treatment for spinal muscular atrophy

Cambridge, mass.--(business wire)--scholar rock (nasdaq: srrk), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, today announced that the u.s. food and drug administration (fda) has accepted its biologics license application (bla) for apitegromab, an investigational muscle-targeted treatment that is being developed to provide clinically meaningful improvement in motor function for.
MAA Ratings Summary
MAA Quant Ranking